PHVIP(LA)848125 is a cyclin dependent kinase (CDK) inhibitor. Oral PHVIP(LA)848125 showed antitumor activity via dual targeting of cyclin-dependent kinase and tropomyosin receptor kinase families in human carcinoma cell and xenografted mouse model of carcinoma.